Prescient Therapeutics Limited (PTX) Earnings Call Transcripts

Prescient Therapeutics Limited's Latest Earnings Call - May 5, 2026

Prescient Therapeutics Limited (PTX:AU) reported its earnings for the fiscal quarter ending March 2026. The company highlighted its cash position at $11.9 million and emphasized its progress in developing PTX-100, a first-in-class GGTase inhibitor targeting the RAS pathway, which affects 22% of cancers. The company did not provide specific revenue or earnings figures, but management focused on the clinical development of PTX-100, particularly its application in cutaneous T-cell lymphoma (CTCL). The company received Fast Track and orphan drug designations from the FDA and EMA, signaling potential expedited pathways to commercialization. No changes to financial guidance were explicitly mentioned.

Reported metrics

Guidance from management

Management did not provide specific financial guidance but indicated that the Phase IIa trial is progressing well, with potential for a Phase IIb registration study if results are favorable.

What management said

Yes. The Dose Optimization Committee will look at the GRS scores and -- Global Response Scores, and they typically come 4 months after the patient is first dosed. So there's a 4-month lead time there.

Yes. The Dose Optimization Committee will evaluate the data from 20 evaluable patients. And so typically, once they hit that point, it's 4 months. They need to get a PET scan, they need to get a number of scans to determine their progress in terms of how well they performed on PTX-100.

What analysts pressed on

Analysts expressed concerns about the pace of patient recruitment and the timing of data readouts. Questions were raised about the potential for early patient results and the impact of regulatory designations on commercialization timelines.

Main topics on the call

• PTX-100 Clinical Progress — PTX-100 is the most advanced inhibitor of GGTase in clinical development, targeting the RAS pathway involved in 22% of cancers. The Phase Ib trials for CTCL showed a 100% clinical benefit rate with no serious adverse eve...
• Regulatory Designations — PTX-100 has received Fast Track and orphan drug designations from both the FDA and EMA. These designations could expedite the approval process and enhance market entry opportunities.
• Market Opportunity — The CTCL market is projected to reach $1.2 billion in the U.S. by 2034. PTX-100's unique mode of action and favorable safety profile position it well to capture market share.
• Phase IIa Trial Recruitment — The company has recruited 18 out of 20 patients needed for the initial cohort in the Phase IIa trial. The Dose Optimization Committee will evaluate data 4 months post-dosing to determine progression to Phase IIb.

Read the full Prescient Therapeutics Limited transcript (May 5, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Prescient Therapeutics Limited earnings call transcripts on record, spanning January 21, 2021 to August 3, 2026. Based on this history, Prescient Therapeutics Limited reports semi-annually. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PTX

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

January 21, 2021

Most recent

August 3, 2026

Reporting cadence

semi-annually